Carospir (Spironolactone) Patent Expiration, LOE Window & CMS Spending

Carospir (Spironolactone) by Cmp Development: FDA Orange Book LOE 2036-10-28, 2 AB generics, $2.7M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCmp Development
FDA Application & PathwayN209478 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-10-28
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$2.7M
2024 Medicare Part D Spend$186K
2024 Medicaid Spend$2.5M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 38.2% 2-yr change)